These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma. Steinberg M; Silva M Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493 [TBL] [Abstract][Full Text] [Related]
3. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Uy GL; Rettig MP; Cashen AF Expert Opin Biol Ther; 2008 Nov; 8(11):1797-804. PubMed ID: 18847313 [TBL] [Abstract][Full Text] [Related]
5. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers. De Clercq E Pharmacol Ther; 2010 Dec; 128(3):509-18. PubMed ID: 20826182 [TBL] [Abstract][Full Text] [Related]
6. Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor. Fadini GP; Fiala M; Cappellari R; Danna M; Park S; Poncina N; Menegazzo L; Albiero M; DiPersio J; Stockerl-Goldstein K; Avogaro A Diabetes; 2015 Aug; 64(8):2969-77. PubMed ID: 25804941 [TBL] [Abstract][Full Text] [Related]
9. Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor. Taubert I; Saffrich R; Zepeda-Moreno A; Hellwig I; Eckstein V; Bruckner T; Ho AD; Wuchter P Cytotherapy; 2011 Apr; 13(4):459-66. PubMed ID: 21077729 [TBL] [Abstract][Full Text] [Related]
10. GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranolol. Sukhtankar DD; Fung JJ; Kim MN; Cayton T; Chiou V; Caculitan NG; Zalicki P; Kim S; Jo Y; Kim S; Lee JM; Choi J; Mun S; Chin A; Jang Y; Lee JY; Kim G; Kim EH; Huh WK; Jeong JY; Seen DS; Cardarelli PM PLoS One; 2023; 18(10):e0287863. PubMed ID: 37878624 [TBL] [Abstract][Full Text] [Related]
11. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation. Flomenberg N; Comenzo RL; Badel K; Calandra G Biol Blood Marrow Transplant; 2010 May; 16(5):695-700. PubMed ID: 20067838 [TBL] [Abstract][Full Text] [Related]
13. Influence of a dual-injection regimen, plerixafor and CXCR4 on in utero hematopoietic stem cell transplantation and engraftment with use of the sheep model. Goodrich AD; Varain NM; Jeanblanc CM; Colon DM; Kim J; Zanjani ED; Hematti P Cytotherapy; 2014 Sep; 16(9):1280-93. PubMed ID: 25108653 [TBL] [Abstract][Full Text] [Related]
14. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Pusic I; DiPersio JF Curr Opin Hematol; 2010 Jul; 17(4):319-26. PubMed ID: 20473162 [TBL] [Abstract][Full Text] [Related]
15. SDF-1/CXCR4 blockade to mobilize hematopoietic progenitor cells from the placenta. Jing D; Alakel N; Bornhäuser M; Ehninger G; Ordemann R Bone Marrow Transplant; 2010 Nov; 45(11):1661-2. PubMed ID: 20173795 [No Abstract] [Full Text] [Related]
16. New agents in HSC mobilization. Domingues MJ; Nilsson SK; Cao B Int J Hematol; 2017 Feb; 105(2):141-152. PubMed ID: 27905003 [TBL] [Abstract][Full Text] [Related]
17. Plerixafor for stem cell mobilization: the current status. Bilgin YM; de Greef GE Curr Opin Hematol; 2016 Jan; 23(1):67-71. PubMed ID: 26554889 [TBL] [Abstract][Full Text] [Related]
18. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613 [TBL] [Abstract][Full Text] [Related]
19. Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4(+) stem cells into the ischaemic heart. Huber BC; Brunner S; Segeth A; Nathan P; Fischer R; Zaruba MM; Vallaster M; Theiss HD; David R; Gerbitz A; Franz WM Cardiovasc Res; 2011 Jun; 90(3):529-37. PubMed ID: 21245057 [TBL] [Abstract][Full Text] [Related]
20. New agents for mobilizing peripheral blood stem cells. Greinix HT; Worel N Transfus Apher Sci; 2009 Aug; 41(1):67-71. PubMed ID: 19615944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]